BG
PETX

BlackRock Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

BlackRock Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,294
Closed -$59K – 3020
2016
Q3 		$59K Buy
+6,294
New +$52.3K ﹤0.01% 2892
2015
Q4 		– Sell
-6,090
Closed -$51K – 3059
2015
Q3 		$51K Buy
6,090
+1,080
+22% +$18.3K ﹤0.01% 2844
2015
Q2 		$76K Buy
5,010
+1,350
+37% +$19.5K ﹤0.01% 2813
2015
Q1 		$59K Buy
+3,660
New +$65.1K ﹤0.01% 2749
2014
Q4 		– Sell
-1,226
Closed -$12K – 2935
2014
Q3 		$12K Buy
+1,226
New +$14.9K ﹤0.01% 2798
2013
Q4 		– Sell
-4,783
Closed -$78K – 2834
2013
Q3 		$78K Buy
+4,783
New +$50.3K ﹤0.01% 2645

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's PETX Position: Q4 2016 in Review

BlackRock Group sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 6,294 shares — an estimated $59K sold.

BlackRock Group first reported a position in PETX in Q3 2013 and held it in 6 quarters. The position peaked at $78K in Q3 2013. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • BlackRock Group reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • BlackRock Group sold 6,294 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $59K.
  • BlackRock Group first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 6 quarters.
  • BlackRock Group's Aratana Therapeutics, Inc. position peaked at $78K in Q3 2013.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.